Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that its subsidiary, Shanghai Haisco Shengno Pharmaceutical Technology Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. The approved clinical trials include HSK45019 tablets, HSK50042 tablets, HSK55718 for injection, and HSK36357 capsules, targeting indications such as inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments